Hims & Hers has a new health product. It is called Peptides+. It offers five new peptide treatments. A peptide is a tiny chain of building blocks from protein. Think of it like a small note that tells your body what to do. The treatments start at $39 a month. The company says doctors guide the care. But the company also says there is still more to learn about how well these treatments work.
What Happened
Hims & Hers launched Peptides+ on Tuesday, November 18, 2026. The launch brings five new peptide treatments to its online health platform. The five treatments are vitamin B-12, glutathione, sermorelin, NAD+, and L-carnitine. Vitamin B-12 starts at $39 a month. L-carnitine starts at $49 a month. Glutathione starts at $59 a month. Sermorelin starts at $99 a month. NAD+ starts at $119 a month. The treatments are made to order for each person. A provider on the Hims & Hers platform writes the prescription. The provider picks the dose and checks on the patient with check-ins and lab tests.
Why It Happened
Peptides have become very popular. Many people talk about them online. Hims & Hers already sells health care online. Adding peptides fits its business. The timing also helped. The federal government recently eased rules on making some unapproved peptide products. Andrew Dudum is the chief executive and co-founder of Hims & Hers. He said, “these molecules are not created equal. There are no two molecules that are the same.” That means each peptide is different. So the company says it picks them with care.
Why It Matters
This launch matters because the treatments are not like normal medicine. These products have not been evaluated or approved by the FDA. The FDA is the group in the United States that checks if a drug is safe and works well. No clinical data for these treatments has been peer-reviewed. Peer-reviewed means other experts have checked the work. Hims & Hers is also clear about what the treatments are not. They are not meant to treat a disease. They are not a weight-loss treatment. You can read about a real weight-loss pill in our post on the Wegovy pill. That pill was tested in a study. The new peptide treatments are a different kind of product. Investors also watched the news. Stock means a small piece of a company. The Hims & Hers stock fell 1% before the market opened on Tuesday. It is down 34% in the past month.
Key Figures
- 5 — new peptide treatments in Peptides+
- $39 a month — lowest starting price, for vitamin B-12
- $119 a month — highest starting price listed, for NAD+
- 1% — how much the stock fell before the market opened on Tuesday
- 34% — how much the stock has fallen in the past month
What Happens Next
Hims & Hers will keep selling Peptides+ on its platform. Providers will keep guiding the care. The company also has a plan for next year. It says it may bring personalized peptide treatments to women in 2027. For now, the launch is aimed at men. You can find more company news in our Business News section.
Final Thoughts
Peptides+ is a big new step for Hims & Hers. The prices are clear and the plan is simple. But the honest part is clear too. These treatments are not approved by the FDA. There is still more to learn about how well they work. That is what the company itself says. So this is a story to watch with care.
Quick Questions
What is Peptides+ from Hims & Hers?
It is a new service with five peptide treatments. A provider on the platform prescribes them. Prices start at $39 a month.
Are the Hims & Hers peptide treatments approved by the FDA?
No. They have not been evaluated or approved by the FDA. The company says there is still more to learn about how well they work.
Are the new peptide treatments for weight loss?
No. They are not a weight-loss treatment. They are also not meant to treat a disease.
Disclaimer: This article is for educational and informational purposes only and does not constitute financial advice.
Sources: CNBC, “Hims & Hers launches new peptide treatments — while admitting there’s more to learn about efficacy,” November 18, 2026; Hims & Hers Newsroom, “Peptides+: Supporting Clinically Guided Care, From the Inside Out,” November 18, 2026.
